Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P K MacCallum

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Hematological Oncology|March 1, 1992
Etoposide in combination with intermediate dose cytosine arabinoside (ID ARA C) given with the intention of further myeloablative therapy for the treatment of refractory or recurrent hematological malignancyJ S Whelan, C L Davis, A Z Rohatiner, et al.
Leukemia|October 1, 1993
Mitoxantrone and cytosine arabinoside as treatment for acute myelogenous leukemia (AML) at first recurrenceP K MacCallum, C L Davis, A Z Rohatiner, et al.
Journal of Thrombosis and Haemostasis : JTH|November 27, 2012
The incidence and magnitude of fibrinolytic activation in trauma patientsI Raza, R Davenport, C Rourke, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Hematological Oncology|March 1, 1992
Etoposide in combination with intermediate dose cytosine arabinoside (ID ARA C) given with the intention of further myeloablative therapy for the treatment of refractory or recurrent hematological malignancyJ S Whelan, C L Davis, A Z Rohatiner, et al.
Leukemia|October 1, 1993
Mitoxantrone and cytosine arabinoside as treatment for acute myelogenous leukemia (AML) at first recurrenceP K MacCallum, C L Davis, A Z Rohatiner, et al.
Journal of Thrombosis and Haemostasis : JTH|November 27, 2012
The incidence and magnitude of fibrinolytic activation in trauma patientsI Raza, R Davenport, C Rourke, et al.
Pageof 4